These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 21979582)

  • 21. A brief overview of amyloids and Alzheimer's disease.
    Ow SY; Dunstan DE
    Protein Sci; 2014 Oct; 23(10):1315-31. PubMed ID: 25042050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease.
    Abskharon R; Seidler PM; Sawaya MR; Cascio D; Yang TP; Philipp S; Williams CK; Newell KL; Ghetti B; DeTure MA; Dickson DW; Vinters HV; Felgner PL; Nakajima R; Glabe CG; Eisenberg DS
    J Biol Chem; 2020 Jul; 295(31):10662-10676. PubMed ID: 32493775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure and Aggregation Mechanisms in Amyloids.
    Almeida ZL; Brito RMM
    Molecules; 2020 Mar; 25(5):. PubMed ID: 32155822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conformation-Specific Association of Prion Protein Amyloid Aggregates with Tau Protein Monomers.
    Ziaunys M; Mikalauskaite K; Krasauskas L; Smirnovas V
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.
    Emadi S; Barkhordarian H; Wang MS; Schulz P; Sierks MR
    J Mol Biol; 2007 May; 368(4):1132-44. PubMed ID: 17391701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis.
    Clos AL; Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Jackson GR; Kelly B; Beachkofsky TM; Kayed R
    Br J Dermatol; 2011 Dec; 165(6):1349-54. PubMed ID: 21729025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Why are Functional Amyloids Non-Toxic in Humans?
    Jackson MP; Hewitt EW
    Biomolecules; 2017 Sep; 7(4):. PubMed ID: 28937655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amyloid by Design: Intrinsic Regulation of Microbial Amyloid Assembly.
    Deshmukh M; Evans ML; Chapman MR
    J Mol Biol; 2018 Oct; 430(20):3631-3641. PubMed ID: 30017921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression.
    De Genst E; Chirgadze DY; Klein FA; Butler DC; Matak-Vinković D; Trottier Y; Huston JS; Messer A; Dobson CM
    J Mol Biol; 2015 Jun; 427(12):2166-78. PubMed ID: 25861763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation.
    Lorenzen N; Nielsen SB; Buell AK; Kaspersen JD; Arosio P; Vad BS; Paslawski W; Christiansen G; Valnickova-Hansen Z; Andreasen M; Enghild JJ; Pedersen JS; Dobson CM; Knowles TP; Otzen DE
    J Am Chem Soc; 2014 Mar; 136(10):3859-68. PubMed ID: 24527756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elucidating the Role of Lipids in the Aggregation of Amyloidogenic Proteins.
    Kurouski D
    Acc Chem Res; 2023 Nov; 56(21):2898-2906. PubMed ID: 37824095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
    Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
    J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers.
    Bitencourt ALB; Campos RM; Cline EN; Klein WL; Sebollela A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A mimotope peptide of Aβ42 fibril-specific antibodies with Aβ42 fibrillation inhibitory activity induces anti-Aβ42 conformer antibody response by a displayed form on an M13 phage in mice.
    Tanaka K; Nishimura M; Yamaguchi Y; Hashiguchi S; Takiguchi S; Yamaguchi M; Tahara H; Gotanda T; Abe R; Ito Y; Sugimura K
    J Neuroimmunol; 2011 Jul; 236(1-2):27-38. PubMed ID: 21641049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
    Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
    Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method.
    Tsukakoshi K; Abe K; Sode K; Ikebukuro K
    Anal Chem; 2012 Jul; 84(13):5542-7. PubMed ID: 22697251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.
    Cascella R; Bigi A; Cremades N; Cecchi C
    Cell Mol Life Sci; 2022 Mar; 79(3):174. PubMed ID: 35244787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.
    Fagerqvist T; Lindström V; Nordström E; Lord A; Tucker SM; Su X; Sahlin C; Kasrayan A; Andersson J; Welander H; Näsström T; Holmquist M; Schell H; Kahle PJ; Kalimo H; Möller C; Gellerfors P; Lannfelt L; Bergström J; Ingelsson M
    J Neurochem; 2013 Jul; 126(1):131-44. PubMed ID: 23363402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade.
    Chiti F; Dobson CM
    Annu Rev Biochem; 2017 Jun; 86():27-68. PubMed ID: 28498720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson's disease.
    Horvath I; Wittung-Stafshede P
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12473-12477. PubMed ID: 27791129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.